Table V.
Distribution of outcome by clinical, morphological and biological features.
| Characteristics | n | Valid, % | Alive | Deceased | Statistic | P-value | Test |
|---|---|---|---|---|---|---|---|
| Gender, n (%) | 0.101 | φ test | |||||
| Male | 64 | 51.5 | 28 (43.8) | 36 (56.2) | |||
| Female | 52 | 48.5 | 8 (15.4) | 44 (84.6) | |||
| Age, n (%) | 0.493 | 0.005 | Kendall's τB | ||||
| <1 year | 28 | 24.2 | 20 (71.4) | 8 (28.6) | |||
| ≥1 year | 88 | 75.8 | 16 (18.2) | 72 (81.8) | |||
| Primary tumor site, n (%) | 0.414 | 0.187 | Cramer's V | ||||
| Suprarenal | 84 | 75.0 | 20 (23.8) | 64 (76.2) | |||
| Retroperitoneal | 24 | 21.4 | 16 (66.7) | 8 (33.3) | |||
| Cervical | 4 | 3.6 | 0 (0.0) | 4 (100.0) | |||
| INSS, n (%) | 0.235 | 0.659 | Cramer's V | ||||
| II | 8 | 6.9 | 4 (50.0) | 4 (50.0) | |||
| III | 16 | 13.8 | 8 (50.0) | 8 (50.0) | |||
| IV | 88 | 75.9 | 24 (27.3) | 64 (72.7) | |||
| IVS | 4 | 3.4 | 0 (0.0) | 4 (100.0) | |||
| Shimada, n (%) | 0.492 | 0.049 | φ test | ||||
| Favorable | 28 | 43.8 | 20 (71.4) | 8 (28.6) | |||
| Unfavorable | 36 | 56.2 | 8 (22.2) | 28 (77.8) | |||
| COG risk, n (%) | 0.448 | 0.067 | Cramer's V | ||||
| Low | 4 | 3.7 | 0 (0.0) | 4 (100.0) | |||
| Intermediate | 8 | 7.4 | 8 (100.0) | 0 (0.0) | |||
| High | 96 | 88.9 | 24 (25.0) | 72 (75.0) |
INSS, International Neuroblastoma Staging System; COG, Children Oncology Group.